GET IN TOUCH

Life Sciencesin BavariaProspering
T H E B AVA R I A N L I F E S C I E N C E I N D U S T R Y

A home forsuccess.
A basis foryour future.
And a variety ofopportunities.

Ambitious goals forthe benefit of all
Bavaria is at the forefront of life science development – both in Germany and Europewide. No other state has defined and implemented such ambitious policies – and they
will benefit us all. Over the last 40 years,
the Bavarian state government has invested€ 500 million in biotechnology alone. These
funds have been complemented by private
sector investments in Bavarian biotech companies of well over € 3.5 billion.
The biotech and medical technology sector in
Bavaria is the biggest life science segment inGermany by a wide margin – and ranked in
the top three in Europe.
With the highest number of biotech startups in Germany in 2014, Bavaria is clearly thelocation of choice for many life science companies. Taken together, it is currently home
to some 900 firms in the biotech, medical
technology and pharmaceutical sectors that
employ tens of thousands of people.

By putting down roots in Bavaria, you too canbe a part of this success. And you’ll be in goodcompany! Multiple national firms and international subsidiaries are located in Bavaria:
A M G E N / B A X A LTA /BAXTER / BIOGEN /B R I S T O L- M Y E R S S Q U I B B /CELGENE / DAICHII SANKYO /G E H E A LT H C A R E / G I L E A D /GLAXOSMITHKLINE / HEXAL /MORPHOSYS / MSD MERCKSHARP & DOHME / MYRIADG E N E T I C S / N O VA R T I S /ROCHE DIAGNOSTICS / SANDOZ /S I E M E N S H E A LT H C A R E /THERMO FISHERS C I E N T I F I C .G E N E A RT /V E RT E X

Bavaria:
the location of choice
for life science
companies

Prospering / The Bavarian Life Science Industry

9

The medical technology
industry in BavariaWith 987 medical technology companies(including suppliers and service providers),
Bavaria is a leader in this sector – both on anational and on a European level. In fact, its
annual revenues of € 9.5 bn in 2014 put it on acomparable level to the industry in the wholeof France (€ 10 bn) and Italy (€ 9 bn). Bavariaalone makes up a third of total German production (€ 22 bn) – and this figure rises to 60 %for radiation and medical imaging, electrotherapy and other electromedical equipment.
Bavarian medical technology companies areoften hidden champions – midsized firmsthat are not yet household names, but are

global leading lights in medical innovation.
They are major job creators too. The German medical technology industry employs
about 170,000 people, with over a third
working in Bavaria (70,000). That makes
Germany the second largest medical technology segment in the world, after theUSA. And there’s strong demand for the
products, as the world market is growing by
6 – 8 % per year. No wonder Bavarian medical technology firms focus on export. In fact,
65 % of their products (based on revenues)
are destined for use in other countries.
With strong growth and high demandfor its products, the medical technology
industry is a major driver of growthin Bavaria

TYPES OF PRODUCTS PRODUCED BY THE
B AVA R I A N M E D I C A L T E C H N O L O G Y I N D U S T R Y

30 %

21 %

19 %

GENERAL
MEDICAL DEVICESDIAGNOSTICS

THERAPEUTIC
DEVICES

11 %

11 %

8%

MEDICAL IMPLANTS

MEDICALI T S O F T WA R E

OTHER PRODUCTS

10

Biotech and pharma
Taking together the entire pharmaceuticaland biotechnology industry in Bavaria – but
excluding the medical technology area – employee numbers reached more than 29,000
in 2014. In addition to the generally stable
employment figures within the industry,around 10,000 employees are working in thelife science departments of Bavarian research

institutions. Bavaria is home to 347 biotech
and pharma companies (figures from 2014),
of which 212 are active in biotech, 62 are contract research organisations, 42 pharma and31 suppliers or CMOs. The Bavarian biotech
industry has enjoyed very rapid growth overthe last 20 years:

B I O T E C H C O M PA N I E S
I N B AVA R I A
212(2014)P EO P L E E M P LOY E D I N
B I O T E C H C O M PA N I E S
11,500(2014)APPROVED MEDIC I N E S B Y B AVA R I A N
BIOTECH SMES
7
(2014)

30(1995)

2500(1995)

0(1995)NUMBER OF
BIOTECH SMESI N B AVA R I A

PRODUCTS AND PIPELINE –D RU G D EV E LO P M E N T
O F B AVA R I A N S M E S(2014)

13
13
15
16

167
INCLUDING:

61

The 20 Bavarian SME drug developers
provide more than 30 % of thenational drug pipeline of SMEs //A total of 112 listed by phase:
Preclinical
Phase II

49
61 Therapeutics & diagnostics //49 Devices & reagents // 16 Agro, food,environment // 15 DNA / protein analytics //13 Bioinformatics //13 Preclinical services

14

33

23

37

5

Phase I
R&D

Phase III

Prospering / The Bavarian Life Science Industry

11Lighthouses
Siemens
Healthcare
Siemens Healthcare is one of the world’s largest suppliers oftechnology to the healthcare industry and a leader in medical
imaging, laboratory diagnostics and healthcare IT. All supported by a comprehensive portfolio of clinical consulting,training, and services available across the globe and tailoredto customers’ needs. In fiscal 2014, Siemens Healthcare hadaround 43,000 employees worldwide and posted a revenue
worth 11.7 billion euros, and profits of more than 2 billion euros.

GE
GE Healthcare is one of the world’s leading
providers of medical technology and services
and the only company whose solutions span
medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery and more. Its GE
Global Research Center Europe, near Munich,is a hub of commercial and industrial scienceand technology innovation.

MorphoSys
MorphoSys, based in Martinsried near Munich, is a leader
in the development of therapeutic antibodies with over 100
different drugs in research and development, one of thebroadest pipelines in the biotech industry. These include
unique approaches to treating conditions such as cancer,
Alzheimer’s disease and others. Founded in 1992, the company went public in 1997.
12

AMGEN
Amgen is the world’s largest independent biotech company. Amgen GmbH in Munich was founded in 1989. Amgen
Research (Munich) GmbH was established in 2012 following
the acquisition of Micromet and employs some 200 R & D
staff; all Amgen sites in Bavaria employ more than 600. In
2014, the FDA approved the cancer drug Blinatumomab (nowBlincyto®), developed in Munich, in record time for its use
to treat a life-threatening acute lymphatic leukaemia that
affects children under 5.

Roche
Diagnostics
GmbH“We are Pharmagnostics” – Roche Diagnostics in Penzberg
near Munich is one of the largest biotechnology centers in
Europe and one of the world’s leading biotech R & D andproduction centers within the Roche Group. It is also thelargest biotech employer in Bavaria with over 5,500 staff.
The company recently invested € 200 m in its new Diagnostics Operations Complex II in response to strong demand for
immuno-diagnostic tests. Roche Diagnostics is committed
to sustainability and recycles waste water as biogas at its
Penzberg facility. The biogas is a renewable energy source
used for heating and other purposes.

Prospering / The Bavarian Life Science Industry13

Cross-Sectoral Projects
ADIDAS / ASTRUM IT / FAUBACKGROUND Adidas, the world’s leading
provider of sports products, together withASTRUM IT, a highly successful Bavarian IT
specialist, and the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) jointly
form the miLife consortium.
PROJECT The goal of the project was to develop an innovative wearable computing
platform to analyze data from sensors integrated in shoes and other clothes to be
used in team sport and health monitoring.
The partners needed to replace isolated
applications by creating a central, flexible
and wearable computing platform, moreadvanced sensor integration as well as
better data analysis and communication
capabilities.
RESULTS The developed application involves
systems that support people playing popularteam sports. It tests the player’s health andfitness and measures performance during
training as well as matches. In addition, thesystem has applications in people’s everyday
life and health. For example, it can motivatethem to take exercise. It also helps doctors
and scientists gather feedback about thehealth and fitness of elderly people and other patients.

DLR
BACKGROUND DLR is Germany’s national
aeronautics and space research centre. DLR
has about 8,000 employees and operates
33 institutes, test and operation facilities. It
has 16 locations in Germany of which 3 are in
Bavaria. Its budget for research and operationsin 2014 was € 871 m. The DLR site at Oberpfaffenhofen in Bavaria is one of Germany’s
largest research centres. It is home to eightscientific institutes and currently employs
more than 1,700 people.
PROJECT DLR developed a robot controlled
by thought. Almost 15 years after being paralysed by a stroke, a 58-year-old US-American
woman was once again able to serve herself
a drink of coffee. Surgeons had implanted
sensors into the woman’s brain more than
five years earlier in the motor area of her cer14

ebral cortex, a thin sheet of neurons on theexterior of the brain that transforms multisensory information into motor commands.
DLR had already developed a robotic armthat could grip and open objects. The challenge for DLR specialists, neuroscientists
and other experts, was to get the robotic arm
to “understand” signals from the sensors
and act on them.
RESULTS Software on a connected computer decoded the signals, and the DLR robot
arm and five-fingered hand executed these
decoded instructions. It took just a few moments for the woman to grasp the drinking
bottle with the robot hand, bring it up to hermouth and drink the coffee through a straw
for the first time in almost 15 years!

Connecting
B AVA R I A N H O T S P O T S I N L I F E S C I E N C E

We focus on
knowledge,
concentrate on
talents and offer
four regions of
excellence toexperience
the wide spectrumof the Bavarian
life sciencelandscape.

Bavarian Hot Spots inLife Science
Over the past 20 years, four life science hot
spots have emerged in Bavaria. Today, they
are all flourishing, internationally recognised
and highly successful.

With biotech and healthcare in Munich,Regensburg and Würzburg, complemented
by an active medical technology scene in the
Nuremberg Metropolitan Region, Bavaria is
the region of choice for life science. We’re withyou every step of the way, offering networking between companies, universities, research facilities, university hospitals, investors, funding authorities and advisers.

If you’re thinking of setting up your life science company or subsidiary in Bavaria, youhave the certainty that you’re surroundedby some of the best brains and resources
the world can offer. Add to that the superb
infrastructure, clusters and quality of life – Over the next few pages, you can find out
and you’ll soon see why Bavaria would be a more about these four regions and what theystrong contender for the life science capital have to offer.
of Europe – and your next investment!

WÜRZBURG
BIOMED AREA

EUROPEAN
M E T R O P O L I TA NREGION OF
NUREMBERG

REGENSBURG
AREA

MUNICH AREA

Connecting / Bavarian Hotspots in Life Science17

Munich Area

THE MUNICH AREA IS ONE OF THE
TOP HOTSPOTS IN EUROPE FOR BIOTECH. With world-renowned universities, excellent research institutions
and its position in the heart of Europe,
it attracts the best talents and provides for the best education and training. Munich biotech com­paniesmainly focus on developing
products and technologies
for use in healthcare.

Weihenstephan-FreisingThis is one of Europe’s major centres ofresearch in green (plant) biotechnologies,
food and nutrition. The campus is home
to a large number of research institutes,
many affiliated with universities, and to astart-up incubation centre.

BIOM –MUNICH BIOTECH
CLUSTERMartinsried
The Life Science Campus forms the heartof Munich’s biotech activities. It’s thehome of the regional cluster BioM as well asnearly half of the region’s biotechs, including the IZB centre of innovation and startup incubation, the Max-Planck Institutes,
the Helmholtz Society, the Gene Centre,
the majority of the Ludwig Maximilian
University (LMU) science departments andthe university hospital. In total, Martinsried regroups more than 150 life science
companies, mainly SMEs.

18

BioM is a non-profit organisation
backed by the Bavarian Ministry of
Economic Affairs. Its mission is tosupport and promote Bavarian biotech start-ups with funding, consulting, coaching, networking andother services. In addition, BioM also
manages the Bavarian Biotechnology
Cluster as part of the Bavarian Cluster
Initiative, with the aim to networking
all the Bavarian biotech areas into one
large regional cluster.
www.bio-m.org

P E R S O N A L I S E D M E D I C I N E AT
AT M
m44
The Munich Biotech Cluster m4
and andits initiativeits initiativem4
Personalised
m4 Personalised
Medicine
Medicine
and and
Targeted
Targeted
Therapies
Therapies
includesincludesover
over
100100partners
partners– biotech– biotech
SMEs,
SMEs,
largelarge
enterprises,
enterprises,scientificscientificbodiesbodiesandandhospitals
hospitals– working– worktogether
ing together
on on
33 33
different
different
projects.
projects.ItItisisfunded
funded bystaff. The TUM has been awarded Excellence
status like LMU and both cooperate withthe following excellence clusters: Centre
for Integrated Protein Science Munich(CIPSM) // Nanosystems Initiative Munich (NIM) // Munich Cluster for Systems
Neurology (SyNergy)

almost €€100
100m
m of
ofpublic
publicand
andprivate
privatefunds.
investment.
PersonPersonalised
alised medicine
medicine
focusesfocuses
on developing
on developing
diagnostic
diagnostic
and therapy
and approaches
therapy approaches
tailored totailoredthe patient’s
to thepatient’s
individual individual
genetic profile
genetic
andprofile
medicalandcondition.
medicalcondition.
www.m4.de
www.m4.de

LUDWIG-MA XIMILIANSU N I V E R S I TÄT M Ü N C H E N
The Ludwig-Maximilians Universität (LMU)
is recognized as one of Europe's premieracademic and research institutions. Since it
was founded in 1472, LMU has attracted inspired scholars and talented students fromall over the world. Today, it has about 50,300
students, 740 professors and 3000 scientificstaff. It has been awarded Excellence status
in the competition run by the German Ministry of Education and Research and the German Research Foundation. The LMU’s new
BioMedical Center (BMC) is located in Martinsried-Grosshadern and offers 18,000 m²of space and the LMU Cell Centre. The university hospital has 2,244 beds and approx.
9000 staff, including 1800 doctors.

MAX PLANCK INSTITUTESThe Max Planck Society operates a numberof research institutions in Germany and inother countries. Max Planck Institutes carryout basic research inter alia in the life sciences, natural sciences and the social and human sciences. In total they have about 17,200
staff including 5,600 scientists.
Max Planck Institute of Biochemistry(MPIB)--Scientists at the MPIB investigate thestructure of proteins and how they function– from individual molecules up to whole organisms.
www.biochem.mpg.de/de

Max Planck Institute of Neurobiology(MPIN)--The MPIN researches the basic functions,structure and development of the brain andthe nervous system.
www.neuro.mpg.de

Max Planck Institute of Psychiatry
T E C H N I S C H E U N I V E R S I TÄT--The main goal of the Max Planck InstituteMÜNCHENof Psychiatry is to gain knowledge about
The Technische Universität München (TUM)
and understanding of the causes of psychicombines top-class facilities for cutting-edge
atric disorders. This knowledge can then beresearch with unique learning opportuniapplied in the development of novel diagties for 37,300 students. It has 500 profesnostic possibilities as well as therapeuticsors and 6,100 staff. Both figures include
and preventive approaches.
the university hospital, Klinikum rechts derwww.psych.mpg.de
Isar, which has 1,100 beds and about 4,500
Connecting / Bavarian Hotspots in Life Science19

H E L M H O LT Z C E N T R E
The Helmholtz Centre Munich is the German
Research Centre for Environmental Health.
It investigates important common diseases
which develop from the interaction of lifestyle, environmental factors and personal
genetic background, focusing particularly on
diabetes mellitus, chronic lung diseases, dementia and others. It has 2,250 employees
including 1,100 scientific staff. Helmholtz isalso one of the facilities involved in the National Cohort, a longtime study of 200,000
healthy people in Germany focusing on research on diet, lifestyle, metabolism and therisk of chronic diseases.
F R A U N H O F E R I N B AVA R I A
Headquartered in Munich and with 23,200
staff, Fraunhofer is Europe’s largest application-oriented research organisation. Its research efforts are geared entirely to people’s
needs: health, security, communication, energy and the environment.
GERMAN RESEARCH CENTREF O R F O O D C H E M I S T RY
The German Research Centre for Food Chemistry is one of the Leibnitz Institutes and isbased in Freising (near Munich). It aims topromote the science of food chemistry, ensuring public welfare and the maintenanceand improvement of the quality of food.
www.dfal.de

H O C H S C H U L E F Ü R A N G E WA N DT E
WISSENSCHAFTENW E I H E N S T E P H A N -T R I E S D O R F
The Hochschule für angewandte Wissenschaften Weihenstephan-Triesdorf specialises in green engineering courses as well as
biotechnology and bioinformatics. In total, it
has 6,300 students and 144 professors.
I N N O VAT I O N A N D
S TA R T- U P C E N T R E F O R
B I O T E C H N O L O G Y,
M A RT I N S R I E D &F R E I S I N G -W E I H E N ST E P H A N
The Fördergesellschaft IZB mbH, founded in
1995, is the operating company of the Innovation and Start-Up Centre for Biotechnology
located in Planegg-Martinsried and Freising
Weihenstephan. It has developed into oneof the top ten biotechnology centres in theworld. Over 60 biotech companies with over
650 employees are located on the 25,000 m²
site. An important criterion for the success of
the IZBs is the close proximity to top researchat the LMU and the renowned biomedical research institutes on the Martinsried
campus, such as the Max Planck Institutes.
The Planegg-Martinsried facility, now spreadover 22,000 m², is home to start-ups focusing on medical biotechnology. Since 2002,
the IZB in Freising-Weihenstephan, with acampus of 3,000 m², offers optimal conditions for company start-ups in the area oflife sciences.
www.izb-online.de/en/about-us.html

20Regensburg Area
The city of Regensburg is 2000 years old andlocated about an hour’s drive from Munich
and Nuremberg. Its BioRegio Regensburg
campus is currently home to 48 life science
companies with a total of about 3500 staff.
That makes it the second largest biotech
region in Bavaria after Munich.

orescent bioanalytics, molecular diagnostics,
biofunctional surfaces, sensors and appliedbiomedicine. It also works with hospitals tooffer interdisciplinary approaches to newmaterials, such as with its new programmeon biomedical engineering focused on medical technology.

U N I V E R S I TÄT R E G E N S B U R G
Universität Regensburg strengths in life
sciences lie in integrated immunopathology
and therapy as well as functional genomics
and transplant medicine. The university hospital has 833 beds and 4,042 staff, of whom
681 are doctors.

B I O PA R K R E G E N S B U R GFounded in 1999 with a € 42 m investment,
the BioPark Regensburg is located on theuniversity campus. It currently houses 36
companies and university facilities, including 11 biotech companies, 7 diagnostics / analytics companies and 3 medical technology
The university hospital also includes the José firms with 600 employees in total.
Carreras Centre for Somatic Cell Therapy www.biopark-regensburg.de(JCC). It was established in 2009 with funds
from the EU and the José Carreras Leukaemia
Foundation. The JCC focuses on the development of new cell therapies for patients withFRAUNHOFER ITEM
cancer or immune diseases. Together with
REGENSBURG AND
several biotech companies, it develops new
PERSONALISED TUMOUR
cutting-edge technologies in the area of cell
THERAPY UNDER
therapy.
P R O F. K L E I N
www.carreras-centrum.de
The goal of this new Fraunhofer project group is to

The Regensburg Centre for Interventional
Immunology (RCI) was established in 2010as a central unit of Regensburg University inorder to regroup all academic research areas
related to the development of new immunotherapies.

gain a deeper understanding of how cancer devel-

www.rcii.deance to medication develops. In addition, they an-ops, make diagnosis more accurate, and prescribe
therapies tailored to each patient. To do this, scientists detect, isolate and analyse the moleculesof individual disseminated tumour cells in early-stage cancer to find out more about how resistalyse information about metastatic precursor cells

O S T B AY E R I S C H E T E C H N I S C H E
HOCHSCHULE REGENSBURG
With about 10,500 students and 220 professors, the OTH Regensburg specialises in flu-

and use the results to develop diagnostic assays
and identify therapeutic targets.
www.item.fraunhofer.de

Connecting / Bavarian Hotspots in Life Science

21

Würzburg BioMed Area
Würzburg has a long tradition in life sciences and molecular biology. X-ray technology
was discovered in Würzburg by Wilhelm
Conrad Roentgen in 1895. The city’s BioMed
area is a renowned centre of biotechnologicaland medical innovations and start-ups. The
city is home to 11 biotech / pharma companies, 44 medical technology companies and
10 institutes / hospitals.

T R A N S L AT I O N A L C E N T E RWÜRZBURGU N D E R P R O F. W A L L E S
The Translational Center Würzburg, a branch of
the Fraunhofer IGB, develops special solutions
for cell-based test systems, processes, applications and (biologically vascularised) implants up
to prototype level. Within this framework, the

JULIUS-MAXIMILIANSU N I V E R S I TÄT W Ü R Z B U R GFounded in 1402, the Julius-Maximilans-Universität is the oldest university in Bavaria.
It currently has 27,900 students and 4,200
staff of whom 2,400 are scientists (incl. 400
professors). Strong fields include medicine,
biology, physics, chemistry and psychology
with the leading interdisciplinary research
centres for infectious diseases, cancer andheart failure as well as regenerative medicine and tissue engineering. The University
Hospital Würzburg has 1,400 beds and 4800
staff (incl. 850 doctors).

22

Translational Center focuses on contract researchfor bio­technological, pharmaceutical and medical
engineering companies and clinics, diagnostic laboratories as well as research facilities. Within the
Bioreactors, Test systems, Theranostics, Implants
and Regulatory Affairs business units, the Translational Center optimises and creates processes,
materials and products for regenerative therapies
from the pre-clinical to the approval stage.
www.igb.fraunhofer.de/de/kompetenzen/translationszentrum-wuerzburg.html

HOCHSCHULE FÜR
A N G E WA N DT E W I S S E N S C H A F T E N
W Ü R Z B U RG -S C H W E I N F U RT
Founded in 1971, this university of appliedscience offers ten faculties with more than
30 bachelor’s and master’s courses and fiveresearch institutes – including the Instituteof Medical Technology – for varied, practicaland future oriented study programmes. It
has 5,800 students.

TELEMEDECINE CENTRE
B A D K I S S I N G E N E . V.
The Bad Kissingen Telemedicine Centre is anassociation focused on gathering and disseminating information about the potentialof remote diagnostics and treatment to improve patient care.
www.ztm-badkissingen.de

I N N O VAT I O N A N D S TA R T- U P
CENTRE, WÜRZBURG
The Würzburg Innovation and Start-Up
Centre was founded in 2001 and focuses on
biomedicine, life sciences, information andcommunication technologies, sensor technology and nanotechnology. Its services include technology scouting in universities,
coaching for start-ups and entrepreneurshipeducation. The centre is currently 90 % fullwith 32 companies (incl. 9 in life sciences)
employing about 360 people.
www.igz.de

Connecting / Bavarian Hotspots in Life Science23

European Metropolitan Area
of Nuremberg
M E D I C A L VA L L E Y E M N E . V.
The Medical Valley in the Nuremberg
Metropolitan Region unites key players from business, science, healthcare
and politics, who work together to advance the healthcare of tomorrow. The
resulting accumulated technology andproblem-solving competency is used todevelop and market effective solutions
tailored to suit global market demands.
The cluster management Medical Valley
EMN e. V. was founded in 2007 in order
to coordinate, develop and market theactivities in the Medical Valley. In 2010
Medical Valley was awarded National Leading-Edge Cluster status by theFederal Ministry of Education and Research. It is very successful, with projected cumulated sales of over € 2.9 bn
for certain cluster projects between
2016 and 2020; and € 1.4 bn savings in
the German healthcare system due to
Medical Valley cluster projects.
www.medical-valley-emn.de

As well as being famous for its delicious
sausages and gingerbread, Nuremberg is
recognised throughout Europe for medical
technology. The Medical Valley is home to500 companies active in medical technology
and 65 hospitals treating over 850,000 inpatients every year. The Nuremberg area boasts
over 80 applied science institutes with afocus on researching and teaching medical
technology. There are over 20 non-academic
research facilities dedicated to medical technology. Many world-leading products andservices were and are developed in the area,
including: Imaging techniques // Intelligent
sensors // Healthcare IT // Ophthalmology// Therapy systems
In addition, 42 % of all German patent applications in the “diagnostics; surgery; identification” category and over 63 % of all German
patent applications in the “X-ray technology”
category come from this region.

SAFETY OF PRESCRIBEDMEDICINES
Drug safety is a strong focus at Medical Valley. In
the Medical Valley Community of Practice, scientific and medical staff work on improving the safetyof medicines in outpatient, inpatient and nursing
care. One of the main missions of the Franconia
Model Region for Digital Healthcare, which wasestablished in 2012, is the optimisation of the
medication process and the safety of prescribed
medicines. The goal is to develop innovative IT
solutions to improve the treatment processes andstructures in the healthcare system.

24

F R I E D R I C H -A L E X A N D E RU N I V E R S I TÄT
ERLANGEN-NÜRNBERGFriedrich-Alexander-Universität (FAU) is oneof the ten largest universities in Germany
and one of the leading universities in Europe. It was classed among the best in 12
out of 31 categories in the EU’s international‘U-Multirank’ ranking. It currently has about
39,000 students and 660 professors. It hasa university hospital with more than 1,300
beds and 7,400 staff, including 1,149 doctors.

O S T B AY E R I S C H E T E C H N I S C H E
HOCHSCHULE
A M B E RG -W E I D E N
The university of applied science AmbergWeiden has two campuses, one in the city ofAmberg and one in the city of Weiden, about
40 km apart. It offers a newly-designed medical engineering course for both bachelor andmaster degrees. In total, the university has
3,500 students and 84 professors.

www.zimt.fau.de

TECHNISCHE HOCHSCHULE
NÜRNBERG GEORG SIMON OHM
Technische Hochschule Nürnberg Georg Simon Ohm is a university of applied scienceswith more than 13,000 students and 300
professors. It includes a Centre for Interdisciplinary Action on Health whose members
work on scientific projects and on the development of devices and software as well ason therapeutic and diagnostic approaches
to action on health. Medical engineering isa major focus, as is rehabilitation for people
with disabilities.

U N I V E R S I TÄT B AY R E U T HFounded in 1975, the University of Bayreuth
offers several courses in life sciences, including biotechnology and chemical engineering,food and healthcare sciences, biochemistry
and molecular biology. The university has atotal of 13,000 students and 1,200 scientificstaff, of whom 224 are professors.

H O C H S C H U L E F Ü R A N G E WA N DT E
WISSENSCHAFTEN ANSBACH
With over 3000 students, Ansbach University’s life science areas include biomedical engineering, industrial biotechnology, and engineering with a focus on medical technology
in cooperation with MedTech Pharma.

The FAU also includes several central institutes such as the Central Institute of Healthcare Engineering (ZiMT). Founded in 2009, it
has played a key role in establishing leading
national and international research projects
and teaching programmes in the field of
medical technology ever since. It is responsible for bringing together the University’s
medical expertise in one organisation andco-ordinating collaboration with industry.

Connecting / Bavarian Hotspots in Life Science25

M E D I C A L VA L L E Y I N N O VAT I O N
A N D S TA R T- U P
I N C U B AT I O N C E N T R E S
Medical Valley Center Erlangen
This business incubator was founded in 2003
and focuses on medical engineering (bothhardware and software). With over 5000 m²of space, it is home to 30 – 40 start-ups. The
Erlangen facility is one of the most successful start-up centres in Germany. It provides
office space and advice to small businesses
as well as contacts and networking opportunities with other companies and institutionsin the medical engineering field.
Medical Valley Center Forchheim
The centre in Forchheim positions itself on
the cusp between medical engineering and
IT. It offers similar services to the Erlangencentre in 4000 m² of office space.
www.medical-valley-center.de26

Internationalisation
Projects
M E D I C A L VA L L E Y
NUREMBERG
M E T R O P O L I TA N R E G I O N

B I O M:OSAKA AND MUNICH
JOIN FORCESThe German government launched the Leading-Edge Cluster Competition in 2007 to takeGermany to the top of the league of technologically advanced nations. Against the backdrop of a funding programme entitled “Internationalisation of Leading-Edge Clusters,
Forward-Looking Projects, and Comparable
Networks”, Medical Valley EMN was one of
the eleven winners and will receive funding
from Germany’s Ministry of Education andResearch of up to € 4 m over the next five
years. Medical Valley plans to extend thestrategic international partnerships it already has with international cluster regionsin Boston (USA), Hong Kong (China) and Porto Alegre (Brazil). This initiative will certainly
benefit the small and medium-sized companies in the Nuremberg area.

The representatives of the biotech clusterorganisations from Munich, Germany, andOsaka, Japan, have signed a transnational
biotech and life-science agreement on close
collaboration between the two regions.
The aim is to pave the way for industry-industry and industry-academia cooperation
between the two regions to make it easierto access interesting markets and promotecollaboration in research.
The partnership covers the exchange of information about new technologies in therespective regions, industrial developments
and academic potential as well as the exchange of best practices in technology transfer and the support of biotech SMEs. Every
year, Bavarian companies are invited topresent at BIO-Japan and are supported via
a joint Bavarian booth organized by BioM andBavaria International.

Connecting / Bavarian Hotspots in Life Science27

Growing
B AVA R I A : A D Y N A M I C S P R I N G B O A R D
F O R S TA R T- U P S

We believe inmaking things
possible.
The future
can’t wait.
We support
innovative ideas –those thatchange lives.

Springboard for Start-Ups
The economic success of any country depends on start-ups and innovative new businesses – and Bavaria’s no exception. Productand service innovation is crucial to keep pacewith international competition and create
jobs. If there’s one thing new entrepreneurs
need to make their innovative ideas a reality,
it’s financing.

The Bavarian Ministry of Economic Affairs
has created its Bavaria Growth Fund of€ 100 million to ensure that promising young
businesses have more venture capital attheir disposal. The fund is managed by Bayern Kapital and co-invests with private venture capital firms as a neutral co-investment
partner to fund growth in Bavaria. Overall,this should mobilise about € 250 million of
growth investment destined for start-ups
in Bavaria.

NEW IDEAS,
NEW PRODUCTS
A N D S E RV I C ES,
AND NEW
BUSINESS MODELSA R E W H AT M A K E
A DYNAMICECONOMYTHRIVE AND
F L O U R I S H . What’s thecommon element
behindall of these?
THE
ENTREPRENEUR.

Growing / Bavaria: a dynamic springboard for start-ups

31

Examples of Bavarian successstories in life scienceswww.morphosys.com

www.amgen.dewww.pieris.com

MORPHOSYS
MorphoSys was founded in 1992 in Martinsried, near Munich, and develops exceptional new treatments for patients
suffering from serious diseases. It is a leader in the field of
therapeutic antibodies. In 2007, MorphoSys signed a longterm alliance with Novartis to become its main technology
collaborator in the area of antibody discovery and development, with a deal value of up to $ 1 billion. Today, MorphoSys’
market capitalisation is over € 1.6 billion.
AMGEN / MICROMET
Micromet was a biotechnology company specialised in the
discovery, development and commercialisation of innovative,
antibody-based cancer therapies. The company developed
an extensive pipeline of novel therapies based on its own
Bispecific T cell Engager (BiTE®) technology. Micromet was
acquired by AMGEN in 2012 for $ 11 per share in cash, valuing Micromet at approximately $ 1.16 billion. In 2014, the FDA
approved the cancer drug Blinatumomab (now Blincyto®),developed by Micromet in Munich, in record time.
PIERIS
Pieris was founded in 2001 in Munich following the
ground-breaking discovery at the Technische Universität
München of Anticalin proteins and their potential as therapeutics. The company has been financed by leading biotechnology-focused venture capital firms since 2002, including
OrbiMed Advisors, Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures,
Bay-Tech Venture Capital, BioM, TCB, KfW and BayernKapital.
In 2011, Pieris signed a discovery deal with Daiichi Sankyo
with a deal value of € 207 million. It has been listed on NASDAQ since mid-2015 and currently has a market capitalisationof about $ 34 million.

32

www.suppremol.com

SUPPREMOL GMBH
SuppreMol, a biopharmaceutical company based in Martinsried near Munich, was co-founded in 2002 by Robert Huber,
the winner of the Nobel prize for chemistry in 1988, as a spinoff from the Max Planck Institute of Biochemistry. The company develops innovative treatments for autoimmune diseases. In early March 2015, SuppreMol GmbH was acquired by
Baxter Inc. for about € 200 million. This was the largest acquisition of a biotech company in Germany for many years.
The acquisition enables the US group to expand into new areas with significant market potential and considerable medical need.
Bayern Kapital was one of SuppreMol’s first investors andbecame a shareholder of the company in 2006. The Series
A financing round in spring 2006 came at a time when it
was very difficult for SuppreMol to obtain venture capital
investment. In this way, Bayern Kapital’s early commitment
contributed considerably to the company’s success.

www.u3pharma.com

U3 PHARMA
Based on the groundbreaking discoveries made by thefounder, the biotech company produced a pipeline of novel
targeted therapeutics and has become a leader in the field oftargeted cancer drug development.
The biotech company has grown to become a leader in thefield of targeted cancer drug development and produced apipeline of novel targeted therapeutics based on the groundbreaking discoveries made by its founder. In 2008, Daiichi
Sankyo Group acquired U3 Pharma in cash with a trans­action
value of about € 150 million and operates the site as European competence centre in oncology.

www.definiens.com

DEFINIENSDefiniens is a leading provider of image analysis and data
mining solutions for tissue diagnostics and clinical digitalpathology. It was founded in 1994 in Munich by Professor
Gerd Binnig, the 1986 Nobel Laureate in Physics. In 2014,
MedImmune, AstraZeneca’s global biological research anddevelopment arm, acquired Definiens for $ 150 million.

Growing / Bavaria: a dynamic springboard for start-ups

33

B AY E R N K A P I TA L
WHO WE ARE
Bayern Kapital GmbH is the public Bavarian
venture capital company and was founded aspart of the “Bavarian Future Initiative” as awholly-owned subsidiary of the LfA FoerderG R Ü N D E R L A N D B AY E R N
bank Bayern (Bavaria's development bank) at
WHO WE ARE
the end of 1995.
In 2014 Ilse Aigner, the Bavarian Minister
for Economic Affairs and Media, Energy andW H AT W E D O
Technology, set up the Gründerland Bayern
The objective of Bayern Kapital is to finance initiative to improve conditions for establishyoung, innovative high-tech companies in ing businesses in Bavaria and to make BaBavaria. Bayern Kapital usually acts as co- varia Germany’s most entrepreneur-friendly
investor in cooperation with a private inves- state with significant European stature.
tor. It plays an important role in improving
venture funding in Bavaria. To date, Bayern
Kapital has invested € 200 million in aboutW H AT W E D O
230 innovative, technology-oriented com- Gründerland Bayern gives potential entrepanies and has € 340 million under mana­ preneurs advice on how to start a company,
gement.
and offers networks and financial support.
In life sciences, Gründerland Bayern helps
www.bayernkapital.dewould-be entrepreneurs leverage the huge
potential that Bavaria offers innovationand technology-oriented start-ups. This isparticularly due to its excellent research infrastructure, global players (DAX blue-chipcompanies) and influential midsized com­
B AY S TA R T U P
panies, many of which are “hidden champiWHO WE ARE
BayStartUP is the Bavarian institution for ons” and world leaders in their sector.
company formation, financing and accelera- www.gruenderland.bayerntion. It is supported by the Bavarian Ministry of Economic Affairs as well as by privatesponsoring partners. BayStartUP helps startups looking for support and capital as wellas companies interested in investment opportunities in the start-up area.
W H AT W E D O
BayStartUP supports innovative start-ups
through the challenges of setting up theircompany and accelerating their growth. We
provide qualified “matchmaking” services tointerested investors, who benefit from access to a broad range of start-ups in various
technology markets.
www.baystartup.de
Growing / Bavaria: a dynamic springboard for start-ups

35SupportingS M O O T H I N G Y O U R PAT H T O S U C C E S S
I N B AVA R I AExcellence needs partners.
We connect and provide a wealth of
networks and organisations to help
you to succeed in Bavaria.
B AVA R I A’ S I N T E R N AT I O N A L
R E P R E S E N TAT I V E S –C O N TA C T S A L L O V E R T H E W O R L D
Since the mid-1990s, the State of Bavaria has been creating a global network of international Bavarian offices.
Bavarian representatives are available to Bavarian companies as German-speaking on-site contacts and contact
enablers, thereby supporting them in developing new export markets as well as in setting up and expanding sales
structures abroad.
Within the scope of “Invest in Bavaria” business location
marketing, the international Bavarian offices promote Bavaria as a high tech location and advise potential investors.
CHILE

PERU

MEXICOCANADAUSA
INDIA

TURKEY
ARGENTINAU N I T E D A R A B E M I R AT E S

SOUTH AFRICACHINA
ISRAELJ A PA N
VIETNAM
CO LO M B I A
RUSSIABRAZILEUROPE

Invest in Bavaria
WHO WE ARE
As the Business Promotion Agency of theState of Bavaria, Invest in Bavaria supports
companies from Germany and abroad andfrom a wide range of sectors in finding theideal location in Bavaria, so that they can be
successful right from the moment they settle here.
W H AT W E D O
Invest in Bavaria offers companies a wealthof services for all stages of setting up a business in the state, from the planning phase,the search for and selection of a location,
through to implementation. Even oncecompanies are successfully settled, Invest
in Bavaria continues to support them, suchas during a planned expansion. The team ofregional advisors complements the services
provided by Invest in Bavaria and gives foreign companies access to Bavaria’s regions.
The regional advisors in this field are characterised by close cooperation and a bilateralexchange of information with the regional
economic promoters. Benefit from the key
advantages we offer you. Our service is freeand confidential. Our team is international
and we are always there for you – both locallyand worldwide. Discover Bavaria’s strengths
with us and open up new opportunities foryour investment project. Choose the ideal
location. Choose Bavaria. And choose Invest
in Bavaria as the expert partner by your side.

1999

F O U N D AT I O N O F
I N V E S T I N B AVA R I A

E V E RY
NEW DIRECT JOBSC R E AT E D T H R O U G H O U T B AVA R I A
SINCE 1999
investment projects
successfully supported since
our foundation

D AY S O N AV E R A G E ,A PROJECT ISS U C C E S S F U L LY
CONCLUDED,C R E AT I N G A R O U N D
45 NEW
DIRECT JOBS

Supporting / Smoothing your path to success in Bavaria

39

Network partners
Medical Valley EMN partners
focus on diagnostic imaging,healthcare IT, intelligent sensors,
ophthalmology andtherapy systems.
en.medical-valley-emn.de

Forum Medtech Pharma
tracks biomaterials, diagnostics,
clinical trials, minimal invasive
medicine, health telematics andhealth care systems.
www.medtech-pharma.org

Founded in 1997,
BioM supports biotechnology
companies andespecially start-ups.
www.bio-m.org

Cooperation is the key to successfor biotech in Bavaria – and the Bavarian Biotech Cluster fosters lively
interaction between all its players.
www.biotech-bavaria.de40

M E D I C A L VA L L E Y E M N E . V.
The Medical Valley in the Nuremberg Metropolitan Region
joins key players from business, science, healthcare andpolitics, which work together to advance the healthcare of
tomorrow. The Medical Valley EMN Association (e. V.) was
founded in 2007 to steer development, coordination andmarketing within the medical engineering cluster. The association supports the 170 members to transfer ideas into
products, organises the exchange of knowledge in the network, promotes the cluster in Germany and internationallyand provides consulting services for start-up companies.
FORUM MEDTECH
P H A R M A E . V.
This Nuremberg-based non-profit association is a networkof over 600 members – companies, research institutes, clinics, health insurance firms, regional authorities and otheractors in the field from 16 countries in Europe, America andAsia. As Europe’s largest network in healthcare, it focuses
on facilitating contacts and partnerships as well as keeping members up to speed on the latest developments withworkshops, conferences, and personal guidance.
BIOM
BioM is a non-profit organisation supported by the Bavarian Ministry of Economic Affairs. Its mission is to promote
Bavarian biotech start-ups with funding, consulting, coaching, networking and other services. In addition, BioM also
manages the Bavarian Biotechnology Cluster (see below)
as part of the Bavarian Cluster Initiative, with the mission
to combine all the Bavarian biotech regions into one large
Bavarian cluster.
B AVA R I A N B I O T E C H C L U S T E R
Bavaria is at the forefront of life sciences in Germany withover 200 biotech companies, along with 150 further firms inpharma, clinical research and development. Its leading position is underscored by the number of approved medicinesderived from biotech SMEs in Germany – 50 % of these areof Bavarian origin.
The Bavarian Biotech Cluster links the biotech locations andstart-up centres throughout the state of Bavaria. These include Munich/Martinsried and Regensburg as well as thenorth Bavarian region (Würzburg, Erlangen, Bayreuth). It
provides information about the sector and helps companies
to establish themselves by providing consultancy, support
and contacts.
One of the Bavarian Biotech Cluster’s main activities is using its close relationships with local academic institutions
to identify commercially viable biotech research projects. It
also promotes the technology and expertise of the firms in
its network on an international level.
By interlinking business and science, the Biotech Cluster
provides a state-wide network that supports and strengthens the entire process – from the original idea to the final
product.

Haus der Forschungoffers all the tools you needto get your R & D projecton track for funding.
www.hausderforschung.bayern.de/en/

HAUS DER FORSCHUNG
The Haus der Forschung is an umbrella organisation re­grouping four innovation advice centres in Bavaria. It provides Bavarian companies and start-ups with integrated
advisory services on funding, including comprehensive information and assistance in the application procedure for EU
funding programs.
ITS GOALS ARE--To increase the efficiency and transparency of technology transfers in Bavaria for the benefit of scientists andbusinesses--To provide broad-based information on funding programmes from the EU, the Federal Republic of Germany
and the state of Bavaria--To secure EU funding for universities and small to midsizedbusinesses by creating consortia that combine businessand scientific actors.

Supporting / Smoothing your path to success in Bavaria

41

Imprint
PLEASE NOTE:This publication is issued as part of the public relations activities of Invest in Bavaria,
the Business Promotion Agency of the Stateof Bavaria, at Bayern International GmbH.
The work is copyright protected. All rights
reserved. This publication is issued free ofcharge; its circulation in return for payment
is forbidden. The publishing of this brochureforms part of the public relations outreachof its publisher, Bavaria‘s government. This
brochure may not be used by any of thestate‘s parties or their candidates or helpers
in the five-month period preceding an election – with this applying to those at the local,
state, national and EU-wide levels – for political purposes. This prohibition particularly
applies to the brochures being distributed atpolitical events and being displayed in theparties’ information booths. No political materials or messages may be inserted into or
stamped and glued on to the brochures. Also
prohibited is the provision of this brochure tothird parties for purposes of securing votes.
Even in those times in which an election is
not pending, this brochure is not allowed to
be used in any way which could be understood as the state government's showing
partisanship towards a political group. Political parties are permitted to use this brochure
as a source of information for their members.

PUBLISHER
Invest in Bavaria –The Business Promotion Agency of theState of Bavaria
at Bayern International GmbH
Invest in BavariaPrinzregentenstraße 22 / 80538 Munich
Phone +49 89 24210-7500 /Fax +49 89 24210-7557
welcome@invest-in-bavaria.com
www.invest-in-bavaria.com
Bavarian Ministryof Economic Affairs and Media,
Energy and Technology
Prinzregentenstraße 28 / 80538 Munich
Phone +49 89 2162-0 /Fax +49 89 2162-2760
poststelle@stmwi.bayern.de
www.stmwi.bayern.de
T E X T A N D L AY O U T
schnellervorlauf gmbh, Ingolstadt
www.schnellervorlauf.de

IMAGE RIGHTS
Image rights an Foto Aigner / Pschierer:
Bavarian Ministry of Economic Affairs andMedia, Energy and Technology; page 7: Science – iStockphoto; page 29: Surfer – Invest
in Bavaria; page 34: Schloss Neuschwanstein – shutterstock; page 37: Lindau harbor –The greatest possible care was employed iStockphotoin compiling this brochure. Notwithstanding this, no guarantees can be furnished as P R I N T
to the correctness and completeness of its Druck + Verlag Ernst Vögel GmbHwww.voegel.com
contents.
Bayern. Die Zukunft.
www.bayern-die-zukunft.de42

KapitelKapitelW W W. I N V E S T- I N - B AVA R I A . C O M